Guidance Capital Inc. Acquires 21,543 Shares of Indivior PLC $INDV

Guidance Capital Inc. acquired a new position in Indivior PLC (NASDAQ:INDV) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 21,543 shares of the company’s stock, valued at approximately $782,000.

Other large investors also recently bought and sold shares of the company. HighTower Advisors LLC purchased a new stake in shares of Indivior during the 2nd quarter valued at about $3,409,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Indivior during the second quarter valued at approximately $7,988,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Indivior during the second quarter valued at approximately $3,332,000. Cookson Peirce & Co. Inc. bought a new position in Indivior during the second quarter valued at approximately $1,390,000. Finally, Two Seas Capital LP lifted its position in Indivior by 5.5% during the third quarter. Two Seas Capital LP now owns 3,671,072 shares of the company’s stock valued at $131,608,000 after purchasing an additional 191,579 shares during the period. 60.33% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the stock in a transaction on Thursday, August 27th. The shares were bought at an average price of $35.69 per share, with a total value of $53,535.00. Following the completion of the purchase, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.74% of the company’s stock.

Analyst Upgrades and Downgrades

INDV has been the topic of several research reports. Wall Street Zen cut shares of Indivior from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd. Craig Hallum restated a “buy” rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Finally, Barclays boosted their price target on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Indivior has a consensus rating of “Buy” and a consensus target price of $46.40.

Indivior Stock Performance

The stock has a market cap of $3.33 billion, a PE ratio of 7.88 and a beta of 0.84. Indivior PLC has a twelve month low of $27.68 and a twelve month high of $42.81. The business has a 50 day simple moving average of $34.90 and a 200 day simple moving average of $35.62.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, October 29th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.26. The business had revenue of $356.00 million for the quarter, compared to analyst estimates of $329.35 million. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. As a group, sell-side analysts predict that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Indivior Announces Dividend

The business also recently disclosed a special dividend, which was paid on Friday, November 6th. Investors of record on Friday, October 30th were given a dividend of $8.13 per share. The ex-dividend date was Tuesday, November 3rd.

Indivior Profile

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.